Research
AHCC
13 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Efficacy ofExtract on Chemotherapy-Related Tasted Disorders in Pancreatic Cancer Patients.
RCT of 98 pancreatic cancer patients undergoing chemotherapy, comparing AHCC to placebo. AHCC significantly reduced the occurrence of taste disorders and improved nutritional parameters compared to placebo, though it did not significantly affect anemia incidence.
An evidence-based systematic review of active hexose correlated compound (AHCC) by the Natural Standard Research Collaboration.
Systematic review of active hexose correlated compound (AHCC) by the Natural Standard Research Collaboration, consolidating safety and efficacy data from scientific literature. Includes analysis of clinical trials, expert opinion, history, pharmacology, interactions, adverse effects, and dosing.
Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
RCT evaluating the effect of AHCC on chemotherapy-related adverse events in 75 unresectable PDAC patients receiving gemcitabine. AHCC intake significantly suppressed CRP elevation and albumin decline, reduced taste disorder frequency, and improved mGPS scores compared to control.
Effect of Active Hexose Correlated Compound (AHCC) in alcohol-induced liver enzyme elevation.
RCT investigating the effects of AHCC supplementation on alcohol-induced liver enzyme elevation. Participants were randomized to placebo, 1 g AHCC, or 3 g AHCC groups for 12 weeks. AHCC groups showed significant improvements in liver enzyme levels and inflammatory cytokines compared to placebo.
Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study.
Prospective cohort study of 269 hepatocellular carcinoma patients post-surgery, comparing those who received AHCC to those who did not. The AHCC group had a significantly longer no recurrence period and increased overall survival rate.
Modulation of T Regulatory and Dendritic Cell Phenotypes Following Ingestion of, AHCCand Azithromycin in Healthy Individuals.
RCT with 40 healthy male volunteers testing the effects of BB536 and AHCC on immune cell modulation following antibiotic usage. The study found increased Foxp3 expression and IFN-γ/IL-4 ratios in the BB536 group, and an increase in myeloid dendritic cells in the combination group, suggesting potential modulation of immune responses.
Effects of active hexose correlated compound on the seasonal variations of immune competence in healthy subjects.
RCT evaluating the effects of active hexose correlated compound intake on immune competence in 34 healthy volunteers. The compound maintained immune competence and natural killer cell numbers during seasonal changes, while the placebo group showed a decline.
Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy--the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy.
This study evaluated the safety and effectiveness of active hexose correlated compound (AHCC) on chemotherapy-induced adverse effects and quality of life in 24 cancer patients. Patients received chemotherapy cycles with and without AHCC. AHCC administration significantly decreased HHV-6 DNA levels in saliva, improved QOL scores, and reduced hematotoxicity and hepatotoxicity.
Short-term supplementation with active hexose correlated compound improves the antibody response to influenza B vaccine.
A randomized controlled study with 30 healthy adults evaluated the effects of AHCC supplementation on the immune response to the 2009-2010 seasonal influenza vaccine. AHCC supplementation increased NKT and CD8 T cells post-vaccination and significantly improved protective antibody titers to influenza B compared to controls.
Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial.
This double-blind, placebo-controlled trial evaluated the effects of AHCC intake on immune responses in 21 healthy volunteers. The AHCC group showed a significantly higher number of total dendritic cells and increased function of DC1s compared to baseline and controls, indicating a positive effect on specific immunity.
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers.
Phase I trial investigating the safety and tolerability of Active Hexose Correlated Compound (AHCC) in 26 healthy subjects. Subjects received 9 g of AHCC daily for 14 days. Adverse effects were mild and transient, with no significant laboratory abnormalities, and the dose was tolerated by 85% of subjects.
Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia.
Single-armed, non-randomized study evaluating AHCC as adjuvant therapy in 29 patients with advanced hepatocellular carcinoma after curative hepatectomy. The 2-year recurrence-free survival rate was 48% for those without discontinuations. AHCC was found to be safe with no observed toxicity or adverse events.
Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment.
Prospective cohort study of 44 patients with advanced liver cancer, comparing AHCC treatment to placebo. AHCC significantly prolonged survival and improved quality of life, with better clinical and immunological parameters observed in the AHCC group.